Clinatec

What Clinatec does

Clinatec is a Grenoble-based biomedical research center founded in 2011, legally organized as a Fonds de Dotation (Clinatec Donation Fund) that supports the Edmond J. Safra Biomedical Research Center. It operates as a nonprofit research entity funded primarily through donations and patronage, and is led by founder Alim Louis Benabid alongside President Thibault Lanxade. Its mission is to develop therapeutic alternatives to medication for conditions where existing treatments are inadequate.

Clinatec's core technical focus is brain-computer interface (BCI) and related implantable neurotechnology, including a proprietary brain-spine interface that has demonstrated restored walking in paralyzed patients and high-speed neural communication reaching 90 characters per minute. Beyond BCI, the organization runs a diversified portfolio of named research projects spanning neurological disease (Alzheimer's, Parkinson's, Lewy Body Disease, traumatic brain injury), sleep disorders (SomniBrain), photobiomodulation / light-based therapy (PBM de Précision, LIghts For hEart), and metabolic disorders (Diabète & Stress). Under the FDA Breakthrough Device Designation framework for Class III medical devices, Clinatec is positioned for potential commercial approvals targeting severe paralysis indications in the 2027-2028 window.

Commercially, Clinatec is pre-revenue: it does not sell products, has no disclosed pricing model, and depends on philanthropic funding, donation flow (via HelloAsso), and institutional support. Its public footprint emphasizes education and stakeholder engagement through professional social channels (LinkedIn, YouTube), newsletters, and press access points, with no traditional distribution or GTM infrastructure. There are no disclosed subsidiaries, no parent company, no M&A activity, and no recurring venture or private equity funding events since a single recorded 2016 inflow of approximately $10.6 million.

Name

Clinatec

Legal name

Fonds de Dotation Clinatec

Website

https://clinatec.fr

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Clinatec is a Grenoble-based biomedical research foundation supporting the Edmond J. Safra center, developing brain-computer interfaces, photobiomodulation, and other medical device technologies for paralysis, Alzheimer's, Parkinson's, traumatic brain injury, diabetes, and motor disabilities.

Ownership category

akta.pro rank

Product category

Neuromodulation and Brain-Computer Interface Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Brain-computer interface
• Neuromodulation devices
• Biomedical research
• Neuroprosthetic implants
• Medical device development

Headquarters

HQ city

Grenoble

HQ country

France

HQ region

Europe

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels4 records

Core offering

Clinatec is a biomedical research center developing implantable brain-computer interface (BCI) technology and micro/nanotechnology-based medical devices aimed at restoring motor and communication functions in patients with paralysis and treating neurological and degenerative diseases. The center advances breakthrough neural implant systems, including a Brain-Spine Interface that has restored walking capabilities and high-speed neural communication achieving 90 characters per minute typing speeds, alongside research into photobiomodulation, sleep disorders, and Parkinson's prevention.

Product overview

Clinatec is a biomedical research foundation affiliated with the Edmond J. Safra Biomedical Research Center that develops medical devices and therapeutic approaches for neurological conditions (Alzheimer's, Parkinson's, traumatic brain injuries), metabolic disorders (diabetes), and motor disabilities. The organization operates through multiple named research projects including Covea NeuroTec (neurological technology), SomniBrain (sleep disorders), Precision Photobiomodulation (light-based therapy), Lewy Body Disease research, LIghts For hEart (cardiac applications), Covea TCC (traumatic brain injuries), Parkinson's Prevention, and Diabetes & Stress studies. Clinatec's product portfolio consists entirely of research projects focused on developing alternatives to medications rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Covea NeuroTec
• SomniBrain
• PBM de Précision (Precision Photobiomodulation)
• Maladie à Corps de Lewy (Lewy Body Disease)
• LIghts For hEart
• Covea TCC (Traumatismes Crâniens)
• Prévention Parkinson
• Diabète & stress (Diabetes & Stress)

Quantifiable outcome

• 90 characters per minute typing speed achieved through neural interface
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Neuralink: Neuralink develops implantable brain-computer interfaces for motor and communication restoration, directly competing with Clinatec's BCI technology for paralysis and motor function indications. Both target FDA Class III approval pathways for implanted neural devices.
• Synchron: Synchron develops a vascular brain-computer interface (Stentrode) for patients with paralysis, making it a direct clinical and regulatory peer to Clinatec's implanted BCI programs. Both have received FDA Breakthrough Device Designation and target similar severe-paralysis indications.
• BrainGate: BrainGate is an academic consortium developing intracortical BCI technology for restoring communication and mobility in paralyzed patients. It is a direct research peer to Clinatec, sharing FDA Breakthrough Designation status and a similar clinical-trial-driven development model.
• Paradromics: Paradromics develops high-data-rate implantable brain-computer interfaces for medical and communication applications. As a direct BCI peer with FDA Breakthrough Designation, it competes with Clinatec on throughput, longevity, and clinical indications for neural implants.
• Blackrock Neurotech: Blackrock Neurotech develops implantable neural interfaces and brain-computer interface systems for research and clinical applications. It is a direct BCI peer with a long-standing implanted-device track record overlapping Clinatec's motor and communication restoration focus.

Broad incumbents

• Medtronic: Medtronic is a broad incumbent in neuromodulation with established deep brain stimulation (DBS), spinal cord stimulation, and implantable neurostimulator franchises. Clinatec's BCI and neuromodulation research competes for the same neurological patient populations and hospital purchasing channels.
• Abbott: Abbott (via St. Jude Medical) operates a broad neuromodulation portfolio including DBS and spinal cord stimulation systems. As an established incumbent with FDA-cleared neurostimulators, it represents both a competitor and a potential strategic acquirer/partner for Clinatec-class BCI programs.
• Boston Scientific: Boston Scientific offers a broad neuromodulation portfolio (Vercise DBS, spinal cord stimulators) and competes with Clinatec in adjacent neurostimulation indications for movement disorders and chronic conditions. Its scale and commercial footprint are key benchmarks for any future BCI commercialization.

Emerging players

• NeuroPace: NeuroPace develops the RNS System, a closed-loop implantable neurostimulator for epilepsy. As an emerging neuromodulation player with FDA approval and commercial experience, it is a relevant comparable for Clinatec's path from Class III trial to commercial launch.
• Saluda Medical: Saluda Medical develops closed-loop spinal cord stimulation systems for chronic pain and is pursuing adjacent neurostimulation indications. It is comparable as an emerging Class III implantable neurostimulator player navigating similar regulatory and clinical-trial hurdles to Clinatec.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCXti1lh4atj34EGWT7V_WLw
• LinkedInlinkedin.com/company/fonds-de-dotation-clinatec
• Xx.com/clinatecfdd

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinatec